These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34571091)

  • 1. The baseline oral microbiota predicts the response of locally advanced oral squamous cell carcinoma patients to induction chemotherapy: A prospective longitudinal study.
    Rui M; Zhang X; Huang J; Wei D; Li Z; Shao Z; Ju H; Ren G
    Radiother Oncol; 2021 Nov; 164():83-91. PubMed ID: 34571091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
    Ren G; Ju H; Wu Y; Song H; Ma X; Ge M; Qiu W; Chen Y; He Y; Zhuang Q; Meng J; Guo W
    Int J Hyperthermia; 2021; 38(1):939-947. PubMed ID: 34134574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
    Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
    J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
    J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
    Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
    Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
    Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stathmin guides personalized therapy in oral squamous cell carcinoma.
    Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
    Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
    Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
    Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
    Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
    Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
    Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
    BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M
    Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer.
    Noronha V; Patil V; Chaturvedi P; Mathrudev V; Menon N; Bhattacharjee A; Singh A; Peelay Z; Chakraborty S; Jadhav M; Alone M; Bhagyavant P; Kolkur M; Srinivas S; Das S; Roy S; Mandal T; Dsouza H; Saha S; Rai R; Srikanth A; Shah D; Khan A; Muthuluri H; Kumar A; Agarwal A; Rajpurohit A; Goli VB; Sekar A; Mantri A; Kanteti APK; Majumdar S; Khaddar S; Shenoy R; Elamarthi P; Rathnasamy N; Kashyap L; Abraham G; Booma N; Simha V; Chaukar D; Pai P; Nair S; Laskar S; Nawale K; Naidu P; Salian S; Shelar P; Raulo R; Dhumal SB; Prabhash K
    Eur J Cancer; 2024 Mar; 200():113560. PubMed ID: 38306841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy of induction chemoimmunotherapy for locally advanced hypopharyngeal carcinoma: a prospective phase Ⅱ study].
    Gong HL; Tian S; Ding H; Tao L; Wang L; Wang J; Wang T; Zhang M; Shi Y; Xu CZ; Wu CP; Wang SZ; Zhou L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):350-356. PubMed ID: 38599645
    [No Abstract]   [Full Text] [Related]  

  • 16. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
    Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
    Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
    Izawa N; Onozawa Y; Hikosaka T; Hamauchi S; Tsushima T; Todaka A; Machida N; Haraguchi Y; Ogawa H; Nishimura T; Nakagawa M; Fuke T; Iida Y; Kamijo T; Onitsuka T; Boku N; Yasui H; Yokota T
    Int J Clin Oncol; 2015 Jun; 20(3):455-62. PubMed ID: 25248339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
    Wen J; Xu H; Liu R; Chen Q; Dai Y; Xu Y
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):24-31. PubMed ID: 32538743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.